SEOUL, South Korea: Lunit INSIGHT MMG integrated into the clinical workflow of Australia’s BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the Go-Live of its collaboration with BreastScreen New South Wales (BSNSW). Initiated as the world’s first integration of AI technology into a national cancer screening program, the BSNSW project has been three years in the making and marks a transformative achievement in advancing early breast cancer detection in the state.